FDA Brief

Warning letters Drugs

FDA warning letter to

LS Promotions Inc.

High riskIssued Aug 5, 2024Posted Aug 13, 2024Division of Pharmaceutical Quality Operations I

LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

What happened

FDA inspected LS Promotions Inc.'s drug manufacturing facility in Ronkonkoma, NY, from April 24 to May 2, 2024. FDA found the company released OTC lip balm, sunscreen, and hand sanitizer without adequate testing of active ingredient identity and strength or microbial quality, without adequate stability data, without process and cleaning validation, and without adequate quality unit oversight.

What FDA found

  1. The company released OTC drug batches without laboratory testing to confirm each active ingredient's identity and strength and without needed microbial testing.

    21 CFR 211.165(a) and 211.165(b)
  2. The company lacked adequate stability data to support storage conditions and expiration dates for its liquid drug products, including a lip balm it further manipulated.

    21 CFR 211.166(a)
  3. The company did not validate its manufacturing processes or equipment qualification, had no bulk hold-time study for the lip balm, and did not show its cleaning procedure works for shared equipment.

    21 CFR 211.100(a)
  4. The quality control unit failed to provide adequate oversight, including procedures, component identity testing, and labeling controls.

    21 CFR 211.22, 211.22(d), 211.84(d)(1), and 211.125(a)

What FDA wants

FDA tells LS Promotions to correct the violations promptly, respond in writing within 15 working days with corrective actions and prevention, and consider engaging a qualified current good manufacturing practice (CGMP) consultant.

Who should pay attention

  • brands or retailers selling LS Promotions OTC products
  • contract manufacturers that fill bulk liquids into finished containers
  • companies relying on supplier expiration dates without stability data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk